Anti-Complement Factor H ELISA
Detection of IgG Antibodies Against Complement Factor H
ELISA-VIDITEST: anti-complement factor H
Comparison of anti-CFH antibody concentration in diseases clinically close to DEAP-HUS.
TTP = thrombotic thrombocytopenic purpura
aHUS = atypical HUS (with CFH or MCP mutation)
DEAP HUS = deficiency of CFHR plasma proteins and factor H autoantibody positive HUS
normal = plasma healthy control
Diagnosis was confirmed by genetic tests.
- First commercially available CE IVD certified ELISA for the detection of anti-CFH antibodies
- High sensitivity/specificity
- Quantitative evaluation of the data
- Incubation at laboratory temperature
- ELISA-VIDITEST anti-complement factor H is intended for the quantitative detection of IgG antibodies against human complement factor H in human serum or plasma.
- Factor H is a complement regulatory glycoprotein that is found in human plasma in concentrations of 300–800 mg/l. Autoantibodies that inhibit factor H function cause complement dysregulation, and they have been detected in about 10% of patients with atypical hemolytic uremic syndrome (aHUS). Atypical HUS is a clinical syndrome that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.
- Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB. Semin Thromb Hemost. 2010 Sep;36(6):633-40.
- Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. J Am Soc Nephrol. 2005 Feb;16(2):555-63.
- Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C.Blood. 2008 Feb 1;111(3):1512-4.